Dysfunction in dopamine (DA) systems is a prominent feature in schizophrenia patients and may result from the abnormal development of mesencephalic (mes)DA systems. Maternal immune activation (MIA) and developmental vitamin D (DVD)-deficiency both induce schizophrenia-relevant dopaminergic abnormalities in adult offspring. In this study, we investigated whether maternal administration of the vitamin D hormone (1,25OHD, VIT D ) could prevent MIA-induced abnormalities in DA-related behaviors and mesDA development. We administrated the viral mimetic polyriboinosinic-polyribocytidylic (poly (I:C)) simultaneously with 1,25OHD and/or their vehicles, to pregnant mouse dams at gestational day 9. Maternal treatment with VIT D prevented MIA-induced hypersensitivity to acute DA stimulation induced by amphetamine, whereas it failed to block prepulse inhibition deficiency in MIA-exposed offspring. MIA and VIT D both reduced fetal mesDA progenitor (Lmx1a + Sox2+) cells, while VIT D treatment increased the number of mature (Nurr1 + TH+) mesDA neurons. Single-cell quantification of protein expression showed that VIT D treatment increased the expression of Lmx1a, Nurr1 and TH in individual mesDA cells and restored normal mesDA positioning. Our data demonstrate that VIT D prevents abnormal dopaminergic phenotypes in MIA offspring possibly via its early neuroprotective actions on fetal mesDA neurons. Maternal supplementation with the dietary form of vitamin D, cholecalciferol may become a valuable strategy for the prevention of MIA-induced neurodevelopmental abnormalities.
SCIENTIfIC REPoRtS | (2018) 8:9741 | DOI:10.1038/s41598-018-28090-w Fetal Tissue Collection and Immunohistochemistry. A second cohort of pregnant dams were prepared and assigned to poly(I:C), VIT D , or appropriate vehicle on GD 9 as described above. The number of dams assigned to each treatment group was N(CON-VEH) = 5, N(CON-VIT D ) = 4, N(POL-VEH) = 5, and N(POL-VIT D ) = 7. Two fetuses per dam were randomly collected (see below), so that the number of fetus in each group was n(CON-VEH) = 10, n(CON-VIT D ) = 8, N(POL-VEH) = 10, and N(POL-VIT D ) = 14.
Fetal mesDA development was assessed at GD11 for the following reasons. First, at this age, the four major mesDA subpopulations we wished to assess (see below) are all present 30 . Second, by GD 11 the elevation in maternal inflammatory cytokines and chemokines induced by MIA has returned to baseline levels [31] [32] [33] , thus removing any active cytokine-mediated cellular effects. Third, the half-life of 1,25OHD is 4-6 hours 34 . Therefore, it is likely the active agent would have been eliminated after 48 hrs.
To collect the fetuses, dams were decapitated without prior anesthesia. The uterus was exposed and collected fetuses were immersion-fixed in 4% paraformaldehyde overnight. Fixed brains were soaked in 30% sucrose solution prior to embedding (Tissue-Tek, Emgrid, Australia). The mesencephalon cryosections were obtained in a one in three series. Sections were immunohistochemically processed simultaneously to eliminate variability. One series was processed for Sox2/Lmx1a, and a second series for Nurr1/TH. Primary antibodies were: rabbit anti-Sox2 (1:200, Millipore Chemicon, Australia), goat anti-Lmx1a (1:100, Santa Cruz Biotechnology, USA), sheep anti-TH (1:100, Novus Biologicals, USA), and rabbit anti-Nurr1 (1:500, Santa Cruz Biotechnology, USA). Fluorophore-conjugated secondary antibodies were diluted 1:1000 (Thermo Fisher Scientific, Australia). Nuclei were stained using 4′,6-diamidino-2-phenylindole (DAPI, 1:1000, Sigma-Aldrich, Australia).
Image acquisition and quantitative immunochemistry.
Immunostaining was assessed using a confocal microscope (Tie, Nikon Inc.) equipped with a Spectral Applied Research's Diskovery spinning disk module with an inverted spinning disk. Images were captured and stitched using NIS software (Nikon Inc.). Images were acquired using 60x oil N.A. 1.4 objective (CFI Apo Lamda/W.D. 0.14 mm), providing a pixel size 0.092 × 0.092 µm 2 . Four mesDA subpopulations were assessed: mesDA progenitors (Lmx1a+Sox2+), post-mitotic (Lmx1a+Sox2−) mesDA neurons, immature (Nurr1+TH−) mesDA neurons, and mature (Nurr1+TH+) mesDA neurons. Briefly, images were background-corrected using ImageJ software and were then analyzed using CellProfiler software (Broad Institute, Massachusetts, USA). This allowed us to quantify cell number, mediolateral/dorsoventral positions, individual protein expression (mean gray value per cell), and nuclear morphological parameters (for image processing and quantitative immunochemistry details see Fig. S2 ).
Statistical Analysis. All data were analyzed using parametric analysis of variance (ANOVA). Percent PPI was analyzed using a 2 × 2 × 3 × 3 (POL treatment × VIT D treatment × pulse level × prepulse level) ANOVA.
In the AMPH sensitivity test, the total distance moved was expressed as a function of 5-min bins and was analyzed by 2 × 2 × 4 (POL treatment × VIT D treatment × 5-min bins) repeated-measure ANOVAs for the initial habituation and saline-treatment phases, and by 2 × 2 × 12 (POL treatment × VIT D treatment × 5-min bins) repeated-measure ANOVA for the subsequent AMPH treatment phase. The quantitative immunochemistry data were analyzed using a 2 × 2 (POL treatment × VIT D treatment) ANOVA using a repeated-measure design (repeated for section intervals). The distribution data were analyzed using a 2 × 2 (POL treatment × VIT D treatment) ANOVA using a repeated-measure design (repeated for bins). Following these initial ANOVAs, restricted ANOVAs or Dunnett's Multiple Comparison Tests were conducted whenever appropriate. Statistical significance was set at p < 0.05.
Results
Effect of maternal VITD treatment on MIA-induced behaviors. Consistent with previous studies 14, 28, 32 , MIA impaired PPI in adult offspring (main overall effect of MIA: F (1,34) = 4.63, p < 0.05; Fig. 1A ). The MIA-induced effect on PPI was driven primarily by a marked reduction the 110 dB A pulse condition (main effect of MIA treatment at the 110 dB A condition: F (1,34) = 13.19, p < 0.001), but not in the 100 or 120 dB A conditions (100 dB A : F (1, 34) = 0.67, p = 0.42; 120 dB A : F (1,34) = 3.04, p = 0.09). Maternal VIT D treatment did not prevent MIAinduced PPI impairments ( Fig. 1A) .
In contrast, maternal VIT D treatment prevented the emergence of AMPH hypersensitivity in offspring exposed to MIA. In line with previous findings 14, 23, 28, 32 , AMPH-induced locomotor activity was increased in MIA offspring (Fig. 1B ). This effect of MIA was blocked when pregnant dams were co-treated with VIT D , leading to a significant three-way interaction between POL treatment, VIT D treatment, and bins (F (11,34) = 1.83, p < 0.05). Subsequent post-hoc group comparisons at each individual 5-min bin confirmed a significant increase in POL-VEH mediated locomotion relative to CON-VEH offspring (all p < 0.05; Fig. 1B ), and between POL-VEH and POL-Vit D offspring at bin 11 and 12 (p's < 0.05; Fig. 1B ). Neither MIA nor maternal VIT D treatment affected locomotor activity in the initial habituation and saline treatment phases of the test (Fig. 1B ).
MIA and VITD treatments both reduce mesDA progenitor number. At GD11, mesDA progenitors are still proliferating 18, 19 . Here we examined mesDA progenitors co-expressing the mesDA specification factor Lmx1a and the neural stem cell transcription factor Sox2 ( Fig. 2A -D and A'-D'). Sox2 is absent in post-mitotic Lmx1a + mesDAs ( Fig. 2C -D and C'-D'). There was a significant interaction between MIA and maternal VIT D treatment on the number of mesDA progenitors (Lmx1a+Sox2 +) (F (1, 36) = 5.19, p < 0.05; Fig. 2E ). Post hoc comparisons revealed that mesDA progenitors were significantly reduced in MIA-treated fetuses (POL-VEH) (F (1,36) = 6.68, p < 0.05), VIT D -treated fetuses (CON-VIT D ) (F (1, 36) = 8.12, p < 0.05) and MIA-VIT D co-treated fetuses (POL-VIT D ) (F (1, 36) Maternal VITD treatment increases the number of mature mesDAs. Consistent with previous studies 18 , immature (Nurr1+TH−) cells were found in the IZ, whereas mature (Nurr1+TH+) cells were largely restricted to the MZ (Fig. 2G -J and G'-J'). MIA and VIT D had no effect on the number of immature mesDAs (p's > 0.05; Fig. 2K ). However, there was a significant main effect of maternal VIT D treatment on mature mesDAs (F (1, 40) = 5.574, p < 0.05; Fig. 2L ). Significant interactions of MIA x VIT D treatments with section position was also found along the anterior-posterior (A-P) axis of the MES (F (6,240) = 2.941, p < 0.05). Post hoc comparison revealed that VIT D treatment itself (CON-VIT D ) increased mature mesDA number relative to control (CON-VEH), particularly in the posterior MES (p's < 0.05).
MIA and VITD treatments affect the position of mesDA progenitors and mature mesDAs.
CellProfiler allowed us to position individual mesDAs in the floor plate (FP). We assessed the average mediolateral (ML) position, (x distance from the midline of the coronal MES section, x 0 ) and average dorsoventral (DV) position (y distance from the most ventral point of the ventricle, y 0 ) ( Fig. 3A,B ).
MIA or VIT D had no effect on the ML or DV positioning of mesDA progenitors (Lmx1a + Sox2+) in the FP (p's > 0.05; Fig. 3C-E ). There were also no significant effects of MIA or VIT D treatments on the average ML positioning of post-mitotic (Lmx1a + Sox2−) mesDAs (p's > 0.05; Fig. 3F ). There was significant interactions between MIA and VIT D treatments on the average DV positioning of post-mitotic (Lmx1a + Sox2−) (F (1, 36) of the acoustic startle reflex was used to investigate sensorimotor gating in adult offspring. %PPI is shown for three startling amplitudes (100, 110 and 120 dB A , which are noted as P-100, P-110 and P-120, respectively) and prepulse intensities (71, 77 and 83 dB A , corresponding to +6, +12 and +18 dB A above background white noise). Poly(I:C) exposure impaired P-110dB A PPI. The bar plots represent the mean %PPI for all prepulse and pulse levels. All values were medians ±SEM. * p < 0.05, reflecting the significant main effect of MIA on mean % PPI; *** p < 0.001, reflecting the significant main effect of MIA in the P-110 condition. (B) The line plot shows total distance travelled in an open field per bin (=5 min) during initial habituation and subsequent saline administration periods, followed by the amphetamine (AMPH; 2.5 mg/kg, i.p.) administration phase. * p < 0.05, reflecting the significant difference between POL-VEH and CON-VEH offspring (AMPH bins 1-9); + p < 0.05, reflecting the significant difference between POL-VEH and POL-Vit D offspring (AMPH bins 11 and 12) . All values were means ± SEM. Fig. 3K ). In addition, there were significant interactions between MIA x VIT D treatments in the average DV positioning of mature (Nurr1+TH+) mesDAs (F (1, 40) = 5.128, p < 0.05; Fig. 3L ). Post hoc comparisons showed that MIA treatment (POL-VEH) reduced the DV positioning of mature mesDAs compared to its control (CON-VEH) (F (1, 40) = 5.871, p < 0.05). Most intriguingly, abnormal DV positioning of mature mesDAs in MIA fetuses was restored by the co-administration of VIT D (POL-VIT D ) (F (1, 40) 
VITD treatment increases the expression of Lmx1a, Nurr1 and TH proteins in mesDAs. mesDA proliferation, specification and differentiation are tightly regulated by the transcription factors Sox2, Lmx1a and Nurr1 18, 19 . CellProfiler analysis allowed us to quantify the protein expression of these factors in individual mesDA cells by measuring the mean fluorescence intensity of these factors.
Sox2 expression. MIA and VIT D had no effect on the mean intensity of Sox2 fluorescence in individual mesDA progenitors (p's > 0.05; Fig. 4B ). Distribution analysis also confirmed Sox2 staining was constant across all treatments (p's > 0.05; Fig. 4C ).
Lmx1a expression.
There was a significant main effect of VIT D treatment on the mean intensity of Lmx1a expression (F (1, 36) = 5.891, p < 0.05), and significant interactions between MIA x VIT D treatments (F (1,36) = 7.993, p < 0.05; Fig. 4E ). Post hoc comparisons revealed that Lmx1a expression was significantly higher in individual cells of CON-VIT D fetuses compared to CON-VEH (p < 0.01) and the other two treatment groups (p's < 0.05). Supporting this, the distribution analysis of Lmx 1a+ demonstrated that more CON-VIT D mesDA cells expressed higher levels of Lmx1a compared to other treatment groups (p's < 0.05; Fig. 4F ).
Nurr1 expression.
There was a significant main effect of VIT D treatment on Nurr1 expression in individual post-mitotic mesDAs (F (1, 40) = 14.451, p < 0.01; Fig. 4H ). Supporting this, the distribution analysis revealed significant main effects of VIT D treatment where more mesDAs had greater Nurr1 expression (F (19, 684) = 6.243, p < 0.01; Fig. 4I ).
TH Expression.
There was a significant main effect of VIT D treatment on TH expression in individual mature (Nurr1+TH+) mesDAs (F (1, 40) = 12.817, p < 0.01; Fig. 4K ). Supporting this, the distribution analysis revealed significant main effects of VIT D treatment where more mature mesDAs had greater TH expression (F (19,684) = 5.301, p < 0.01; Fig. 4L ).
Discussion
VITD abolishes MIA-induced sensitivity to AMPH. Rodent models of MIA and DVD-deficiency both exhibit early molecular and behavioural abnormalities consistent with altered DA signaling 6,7,10,35 , suggesting a common pathogenic pathway 6 . In support of this hypothesis, the present study shows that co-administration of VIT D during gestation prevents the MIA-induced potentiation of AMPH sensitivity in adult offspring. It thus appears that the process leading to AMPH hypersensitivity in MIA offspring is initiated during early fetal development, such that interventions targeting the initiation process (e.g., through co-administration of VIT D during gestation) are capable of preventing the subsequent establishment of this phenotype.
The failure of VIT D to block MIA-induced impairments in PPI may seem counterintuitive at first, given that dopaminergic mechanisms have also been implicated in this association 11, 36 . More specifically, previous studies found that acute and chronic administration of DA receptor antagonists in adulthood and adolescence, respectively, mitigated PPI deficits in adult MIA offspring 11, 36 . While these findings clearly point to an involvement of the DA system in the adolescent and/or adult expression of PPI, they are not informative with regards to the underlying developmental processes occurring prior to adolescence. Based on the present data, we propose that MIA-induced alterations in PPI and AMPH sensitivity have a differential ontogeny. This hypothesis is also consistent with our previous findings showing that (i) whilst DVD-deficiency induces locomotor sensitivity to AMPH 13 , it does not impair PPI 12 , and (ii) MIA-induced PPI impairments are not critically dependent on the mesDA differentiation and maintenance factor, Nurr1 37 , the latter of which we find to be deregulated in the fetal brain after DVD-deficiency or MIA.
The acute elevation of inflammatory cytokines is proposed as one of the primary pathways leading to neuropsychiatric phenotypes in MIA offspring 35, 38 . Given the well-known anti-inflammatory actions of vitamin D, this could well represent its neuroprotective mechanism 39 . However, we have previously reported that VIT D co-treatment in this model failed to affect poly(I:C)-induced elevations in IL-6, IL-1ß and TNF alpha, in either maternal serum or fetal brain 27 . Although there may be other inflammatory factors/processes involved 40 , our current findings suggest an alternative neuroprotective mechanism. Based on our novel data presented here, we believe that maternal VIT D may exert its beneficial effects through actions on the developing DA system. channel-merged image (J). (G'-J') Higher magnification images of the dashed outlined boxes representing FP from (G-J) accordingly. Immature Nurr1+ mesDAs were primarily located in the IZ and MZ. Mature (Nurr1+ TH+) mesDAs were primarily located in MZ. (K) There were no significant differences of immature mesDA number among treatment groups (p's > 0.05). (L) VIT D treatment itself increased mature (Nurr1+ TH+) mesDA number compared to its vehicle (VEH) (p < 0.05). VIT D treatment itself (CON-VIT D ) particularly increased mature mesDA number in the posterior MES compared to control (CON-VEH) (p's < 0.05). All values were means ± SEM. * P < 0.05. n.s., represents not statistically significant. Scale bars: 100 µm (A-D and G-J); 50 µm (A'-D' and G'-J'). Both MIA and VITD decrease mesDA progenitor numbers, but only VITD increases mature mesDA number. All maternal treatments reduced mesDA progenitor (Lmx1a+Sox2+) numbers. There are likely to be distinct mechanisms for these effects, and consequences thereof as well. Whilst the MIA-induced reduction in mesDA progenitor cells was accompanied by the subsequent emergence of behavioral deficits, maternal VIT D was without consequences on offspring behavior per se. Mechanistically, the effects of MIA on mesDA progenitor numbers likely involve the inhibition of neural progenitor formation via signaling at toll-like 3 receptors (TLR3), which are expressed early in the embryonic brain 41 . The pro-inflammatory cytokines induced by MIA can inhibit neural proliferation as well [42] [43] [44] .
Contrary to MIA, maternal VIT D may reduce mesDA progenitor numbers by means of shifting the progenitor cells to a more differentiated phenotype. Indeed, the pro-differentiation properties of VIT D in neurons and in the brain are well described. In vitro VIT D treatment differentiates neural stem cells into neurons 45 ; SH-SY5Y cells into DA neurons 21, 22 and inhibits neural progenitor formation 46 . In contrast, the absence of vitamin D during gestation leads to effects that are diametrically opposite to those reported here, namely an increase in mitosis across multiple brain regions 47, 48 and enhanced neural progenitor formation 46 .
Importantly, our study further shows that VIT D and MIA have divergent effects on mature (Nurr1+TH+) mesDA neuron number. Although not significant, MIA clearly appeared to reduce (Nurr1 + TH+) mesDA cell number. In contrast, VIT D increased (Nurr1+TH+) mesDA number, particularly for the more posterior mesDAs (Fig. 2L) . A VIT D -mediated restoration of TH cell number therefore represents one plausible mechanism for the normalization of DA-mediated behaviours in MIA exposed offspring.
VITD restores MIA-induced alterations in the distribution of mesDAs.
For post-mitotic neurons, we show that MIA alters the mean DV positioning of post-mitotic (Lmx1a+Sox2−) mesDAs and the ML positioning of mature (Nurr1+TH+) mesDAs. VIT D co-treatment did not rescue these deficits. However when examining the DV positioning of mature mesDAs, we show a profound MIA-induced reduction in DV positioning, which was fully prevented by VIT D . Importantly, VIT D by itself had no effect on ML or DV positioning of any mesDA neuron type. Therefore, the correction of early mis-positioning of mesDA neurons by VIT D could represent another plausible mechanism for the normalization of DA-mediated behaviours in MIA-exposed offspring.
VITD regulates protein expression of key mesDA factors. VIT D treatment increased the expression
of all mesDA-related proteins examined. In contrast, MIA by itself had no significant effects on the expression of these proteins.
Here, we show that VIT D treatment upregulates the expression of Lmx1a in developing mesDAs. Lmx1a is a convergent upstream molecule from SHH-Wnt pathways that specify mesDA lineage [49] [50] [51] . SHH and Wnt signaling are affected in MIA and DVD-deficiency models respectively 14, 21 .
Nurr1 a direct upstream target of Lmx1a promotes mesDA differentiation 49, 50, 52 . MIA and DVD-deficiency reduce the mRNA expression of Nurr1 in the fetal brain 14, 15 . This is consistent with present cell counting data, which indicates a recognizable (but not significant) reduction in Nurr1 + cell number in MIA embryos. At an individual cell level, however, the remaining cells have normal Nurr1 protein expression. Therefore, the likely explanation for previous findings showing reduced Nurr1 mRNA expression in MIA fetuses is a reduction in cell number 14 . Importantly, genetic deficiency of Nurr1 has previously been shown to induce AMPH hypersensitivity in a similar way to MIA 53 . Therefore the promotion of Nurr1 expression by VIT D may represent a third mechanism for the prevention of AMPH hypersensitivity in MIA exposed offspring.
Lmx1a and Nurr1 regulate the expression of TH 54, 55 . We have shown VIT D elevates TH mRNA and protein in neuroblastomas in culture 21, 22 . Again consistent with these findings the absence of VIT D in DVD-deficiency leads to the downregulation of TH in fetal rodent brains 16, 20 . Here, we verified that VIT D increases the expression of TH in vivo.
In summary VIT D increases the expression of the mesDA transcription factors (Lmx1a and Nurr1) and the rate-limiting enzyme in DA synthesis (TH) in developing mesDA cells. The expression of these three factors in control mesDAs clearly increases with differentiation state (Fig S4) . Therefore VIT D acts to differentiate the remaining mesDAs in MIA-exposed embryos. This represents a highly plausible mechanism for the prevention of DA-related behavioural deficits induced by MIA. Given that VIT D treatment itself has no effect on the behaviours examined here and those examined previously 27 , we conclude that the accelerated maturation effects of VIT D treatment alone on mesDAs is benign.
(G) There were significant interactions between MIA or VIT D treatments on the average DV positioning of post-mitotic (Lmx1a+Sox2−) (p < 0.05). MIA treatment (POL-VEH) reduced the DV positioning of postmitotic mesDAs compared to its control (CON-VEH) (p < 0.05). (H) A representative FP of a coronal MES section showing cells that were triple-labeled by DAPI (blue), Nurr1 (magenta) and TH (green). There were no significant effects of MIA or VIT D treatment for the mean ML (I) or DV (J) positioning of immature (Nurr1+TH−) mesDAs in the FP (p's > 0.05). (K) MIA treatment (POL) reduced the mean ML positioning of mesDAs relative to CON (p < 0.05). (L) There were significant interactions between MIA x VIT D treatments in the average DV positioning of mature (Nurr1+TH+) mesDAs (p < 0.05). Post hoc comparison revealed MIA treatment (POL-VEH) decreased the mean DV positioning relative to the control (CON-VEH) (p < 0.05). Additionally, the co-treatment of VIT D restored the mean DV positioning of mature mesDAs in POL-VIT D group compared to POL-VEH group (p < 0.05). All values were means ± SEM. * p < 0.05. n.s. represents not statistically significant. Scale bars: 50 µm. 
Limitations
Although our findings provide more data for the translational relevance of introducing dietary intervention during early pregnancy for the prevention of developmental psychiatric diseases, the direct supplementation of the hormonal form of vitamin D, 1,25OHD, to pregnant women would adversely affect calcium in the developing embryo and therefore is not clinically feasible. Therefore preclinical replication studies are now warranted using the safe to use dietary form of vitamin D, cholecalciferol. In this study, we have only investigated one developmental time point and only male foetuses. In future studies, it will be obviously important to examine the entire ontogeny of mesDA systems in both sexes to understand long-term outcomes.
Conclusion
This study represents a small but growing number of preclinical studies showing that the trajectory of adverse MIA-induced outcomes for adult brain function can be diminished or averted by dietary interventions. Two such studies have employed dietary interventions in MIA-exposed juvenile offspring with either a ketogenic diet or glucoraphanin to reverse certain MIA-induced behavioural phenotypes of relevance to psychiatry 56, 57 . Of closer relevance to our study Weiser and colleagues have supplemented MIA dams with docosahexaenoic acid and prevented the onset of autistic-like phenotypes 58 . We recently reported that maternal treatment with VIT D blocked the emergence of MIA-induced deficits in cognitive and social behavioural phenotypes of relevance to autism in offspring 27 . Using a mouse model of MIA, the present study is the first to reveal preventive effects of maternal VIT D treatment on AMPH hypersensitivity, a phenotype with relevance to the positive symptoms of schizophrenia [59] [60] [61] .
We further identify three plausible pathways via which VIT D may act to restore or support normal DA development in the event of MIA. First, MIA retarded the positioning of mesDAs particularly in the DV dimension, whereas VIT D treatment restored this at least for TH+ mesDA neurons. Second, MIA appeared to reduce TH+ cell number, while at the same time, VIT D increased TH+ mesDA cells. Third, VIT D increased the expression of proteins consistent with a more differentiated mesDA neuron. These three processes likely reflect an accelerated differentiation of DA neurons induced by VIT D , which in turn may have protected against the emergence of AMPH hypersensitivity in adult MIA offspring. By contrast, MIA-induced PPI deficiency does not seem to critically involve the same developmental pathways.
This data adds to a steadily increasing literature indicating developing DA systems may be particularly vulnerable to adverse environmental factors such as MIA and DVD-deficiency and represent a plausible convergent early mechanistic pathway to psychiatric disorders such as schizophrenia.
